文献速递中医内科针灸推拿中医康复

温肺固元脐灸治疗稳定期慢性阻塞性肺疾病的多中心随机对照试验

Effects of Wenfei Guyuan umbilical moxibustion on patients with stable chronic obstructive pulmonary disease: A multicenter randomized controlled trial.
PubMed 文献 · Complement Ther Med · 2025-05-22

本研究为多中心、开放标签随机对照试验,纳入220例稳定期COPD患者,1:1随机分为温肺固元脐灸联合常规药物组与常规药物组,治疗13周并随访26周。结果显示试验组在减少急性加重频率、改善6分钟步行距离、mMRC评分及临床症状体征评分方面优于对照组,肺功能FVC和FEV1未见显著改善,皮肤致敏发生率组间无统计学差异。

要点

  • 温肺固元脐灸联合常规药物可减少稳定期COPD患者急性加重频率。
  • 该疗法可改善运动耐量、呼吸困难严重程度及临床症状体征评分。
  • FVC和FEV1未见显著改善,FEV1%仅见组间效应。

核心结论

  • 温肺固元脐灸联合常规药物在减少稳定期COPD急性加重频率、提高运动耐量、减轻呼吸困难及改善生活质量方面优于常规药物。
  • 该干预在稳定期COPD治疗中显示出有效性和安全性。

研究设计与样本

  • 多中心、开放标签、随机对照试验,共纳入220例受试者,按1:1随机分为试验组(温肺固元脐灸联合常规药物)和对照组(常规药物)。
  • 两组均治疗13周,随后随访26周;215例完成试验。

主要发现

  • 急性加重频率存在显著时间效应(P < 0.001)和组间效应(P = 0.001),无交互效应(P = 0.406)。
  • 与对照组相比,试验组在治疗4周、13周及随访13周、26周时急性加重频率显著降低(P < 0.05)。
  • 6分钟步行距离、mMRC评分及临床症状体征评分(咳嗽、咳痰、喘息、胸闷、气短、乏力、发绀及总分)在不同时间点存在显著时间效应、组间效应和交互效应(P < 0.05)。
  • FVC和FEV1无时间效应、组间效应或交互效应(P > 0.05);FEV1%存在组间效应(P < 0.05),无时间效应或交互效应(P > 0.05)。
  • 试验组总体皮肤致敏发生率为3.74%,略高于对照组的0%,但组间差异无统计学意义(P > 0.05)。

临床怎么用

  • 可将温肺固元脐灸作为稳定期COPD常规药物治疗的辅助干预,以降低急性加重频率并改善症状与运动耐量。
  • 治疗期间需关注皮肤致敏反应,尽管本研究中组间差异无统计学意义。

局限性

  • 本研究为开放标签设计,可能存在实施偏倚。
  • 随访时间为26周,长期疗效尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease. Its high disability rate, high mortality rate, and heavy economic burden have made it a major public health problem. Umbilical moxibustion has been reported to have therapeutic effects on COPD, but there is a lack of high-quality evidence-based studies on this intervention. Therefore, the purpose of this study is to evaluate the efficacy and safety of Wenfei Guyuan (WFGY) umbilical moxibustion in the treatment of COPD. METHODS: This was a multicenter, open-label, randomized controlled trial (RCT). A total of 220 participants were randomly assigned at a 1:1 ratio to the experimental group (WFGY umbilical moxibustion in combination with conventional drugs) and the control group (conventional drugs). Both groups received 13 weeks of treatment, followed by 26 weeks of follow-up. The primary outcome was the frequency of acute exacerbations, and the secondary outcomes were the 6-minute walk distance (6MWD), modified Medical Research Council dyspnea scale (mMRC) score, clinical symptoms and signs scores, and lung function tests. Statistical analysis was performed using SPSS software (version 25.0). RESULTS: A total of 220 participants were included in the study, and 215 participants completed the trial. There were significant time effects and group effects on the frequency of acute exacerbations (P < 0.001, P = 0.001), but no interaction effects (P = 0.406). Compared with the control group, the frequency of acute exacerbations in the experimental group was significantly reduced at 4 and 13 weeks of treatment and at 13 and 26 weeks of follow-up (P < 0.05). Among the secondary outcomes, there were significant time effects, group effects, and interaction effects on the 6MWD, mMRC scores, and clinical symptoms and signs scores (cough, expectoration, wheezing, chest tightness, shortness of breath, fatigue, cyanosis, and total scores) at different time points between the two groups (P < 0.05). FVC and FEV1 had no time effects, group effects, or interaction effects (P > 0.05). FEV1 % had group effects (P < 0.05) but no time effects or interaction effects (P > 0.05). The overall skin sensitization incidence in the experimental group was 3.74 %, which was slightly higher than the 0 % incidence in the control group, but no statistically significant difference was observed between the two groups (P > 0.05). CONCLUSIONS: The experimental group demonstrated superior efficacy to the control group in reducing the frequency of acute exacerbations, enhancing exercise tolerance, reducing dyspnea severity, and improving quality of life. This intervention demonstrated effectiveness and safety in the treatment of stable COPD, providing a foundation for further research. TRIAL REGISTRATION: https://www.chictr.org.cn, ChiCTR2100049802. Registered on August 9, 2021.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Xiao Q, Meng Y, Wang G, et al. Effects of Wenfei Guyuan umbilical moxibustion on patients with stable chronic obstructive pulmonary disease: A multicenter randomized controlled trial. Complement Ther Med. 2025. PMID: 40412727. doi:10.1016/j.ctim.2025.103194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。